[go: up one dir, main page]

HRP20100263T1 - Ciklopropil amini kao modulatori histaminskog h3 receptora - Google Patents

Ciklopropil amini kao modulatori histaminskog h3 receptora Download PDF

Info

Publication number
HRP20100263T1
HRP20100263T1 HR20100263T HRP20100263T HRP20100263T1 HR P20100263 T1 HRP20100263 T1 HR P20100263T1 HR 20100263 T HR20100263 T HR 20100263T HR P20100263 T HRP20100263 T HR P20100263T HR P20100263 T1 HRP20100263 T1 HR P20100263T1
Authority
HR
Croatia
Prior art keywords
cyclopropyl
piperazin
ylmethyl
phenyl
methanone
Prior art date
Application number
HR20100263T
Other languages
English (en)
Inventor
D. Allison Brett
I. Carruthers Nicholas
A. Grice Cheryl
A. Letavic Michael
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of HRP20100263T1 publication Critical patent/HRP20100263T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/38—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Spoj, naznačen time, da je izabran iz skupine koju čine: (4-ciklopropil-piperazin-1-il)-(4-morfolin-4-ilmetil-fenil)-metanon, (4-ciklopropil-piperazin-1-il)-[4-(4-fluoro-piperidin-1-ilmetil)-fenil]-metanon, (4-ciklopropil-piperazin-1-il)-(4-tiomorfolin-4-ilmetil-fenil)-metanon, te (4-ciklopropil-piperazin-1-il)-[4-(2-hidroksimetil-morfolin-4-ilmetil)-fenil]-metanon, te njihovi enantiomeri, hidrati, solvati i farmaceutski prihvatljive soli. Patent sadrži još 27 patentnih zahtjeva.

Claims (28)

1. Spoj, naznačen time, da je izabran iz skupine koju čine: (4-ciklopropil-piperazin-1-il)-(4-morfolin-4-ilmetil-fenil)-metanon, (4-ciklopropil-piperazin-1-il)-[4-(4-fluoro-piperidin-1-ilmetil)-fenil]-metanon, (4-ciklopropil-piperazin-1-il)-(4-tiomorfolin-4-ilmetil-fenil)-metanon, te (4-ciklopropil-piperazin-1-il)-[4-(2-hidroksimetil-morfolin-4-ilmetil)-fenil]-metanon, te njihovi enantiomeri, hidrati, solvati i farmaceutski prihvatljive soli.
2. Spoj u skladu sa zahtjevom 1, naznačen time, da je (4-ciklopropil-piperazin-1-il)-(4-morfolin-4-ilmetil-fenil)-metanon ili njegov enantiomer, hidrat, solvat ili farmaceutski prihvatljiva sol.
3. Spoj u skladu sa zahtjevom 1, naznačen time, da je (4-ciklopropil-piperazin-1-il)-[4-(4-fluoro-piperidin-1-ilmetil)-fenil]-metanon ili njegov enantiomer, hidrat, solvat ili farmaceutski prihvatljiva sol.
4. Spoj u skladu sa zahtjevom 1, naznačen time, da je (4-ciklopropil-piperazin-1-il)-(4-tiomorfolin-4-ilmetil-fenil)-metanon ili njegov enantiomer, hidrat, solvat ili farmaceutski prihvatljiva sol.
5. Spoj u skladu sa zahtjevom 1, naznačen time, da je (4-ciklopropil-piperazin-1-il)-[4-(2-hidroksimetil-morfolin-4-ilmetil)-fenil]-metanon ili njegov enantiomer, hidrat, solvat ili farmaceutski prihvatljiva sol.
6. Spoj u skladu sa zahtjevom 2, naznačen time, da je izabran iz skupine koju čine (4-ciklopropil-piperazin-1-il)-(4-morfolin-4-ilmetil-fenil)-metanon i (4-ciklopropil-piperazin-1-il)-(4-morfolin-4-ilmetil-fenil)-metanon dihidroklorid.
7. Spoj u skladu sa zahtjevom 6, naznačen time, da je (4-ciklopropil-piperazin-1-il)-(4-morfolin-4-ilmetil-fenil)-metanon.
8. Spoj u skladu sa zahtjevom 6, naznačen time, da je (4-ciklopropil-piperazin-1-il)-(4-morfolin-4-ilmetil-fenil)-metanon dihidroklorid.
9. Spoj u skladu sa zahtjevom 2, naznačen time, da je (4-ciklopropil-piperazin-1-il)-(4-morfolin-4-ilmetil-fenil)-metanon citratna sol.
10. Spoj u skladu sa zahtjevom 1, naznačen time, da je (4-ciklopropil-piperazin-1-il)-[4-(4-fluoro-piperidin-1-ilmetil)-fenil]-metanon citratna sol, (4-ciklopropil-piperazin-1-il)-(4-tiomorfolin-4-ilmetil-fenil)-metanon citratna sol ili (4-ciklopropil-piperazin-1-il)-[4-(2-hidroksimetil-morfolin-4-ilmetil)-fenil]-metanon citratna sol.
11. Farmaceutski pripravak, naznačen time, da sadrži farmaceutski prihvatljivu podlogu i učinkovitu količinu najmanje jednog spoja izabranog iz skupine koju čine: (4-ciklopropil-piperazin-1-il)-(4-morfolin-4-ilmetil-fenil)-metanon, (4-ciklopropil-piperazin-1-il)-[4-(4-fluoro-piperidin-1-ilmetil)-fenil]-metanon, (4-ciklopropil-piperazin-1-il)-(4-tiomorfolin-4-ilmetil-fenil)-metanon, te (4-ciklopropil-piperazin-1-il)-[4-(2-hidroksimetil-morfolin-4-ilmetil)-fenil]-metanon, te njihovi enantiomeri, hidrati, solvati i farmaceutski prihvatljive soli.
12. Najmanje jedan spoj izabran iz skupine koju čine: (4-ciklopropil-piperazin-1-il)-(4-morfolin-4-ilmetil-fenil)-metanon, (4-ciklopropil-piperazin-1-il)-[4-(4-fluoro-piperidin-1-ilmetil)-fenil]-metanon, (4-ciklopropil-piperazin-1-il)-(4-tiomorfolin-4-ilmetil-fenil)-metanon, te (4-ciklopropil-piperazin-1-il)-[4-(2-hidroksimetil-morfolin-4-ilmetil)-fenil]-metanon, te njihovi enantiomeri, hidrati, solvati i farmaceutski prihvatljive soli, naznačen time, da se koristi u liječenju ili prevenciji CNS poremećaja izabranog iz skupine koju čine: neurološki poremećaji uključujući i poremećaje spavanje/buđenje i napetost/opreznost (na primjer nesanica i promjena vremenskih zona (jet lag)), hiperaktivni poremećaji s deficitom pozornosti (ADHD), poremećaji učenja i pamćenja, kognitivna disfunkcija, migrena, neurogena upala, demencija, blago kognitivno oštećenje (pre-demencija), Alzheimer-ova bolest, epilepsija, narkolepsija s ili bez pridružene katapleksije, katapleksija, poremećaji homeostaze spavanje/buđenje, idiopatska somnolencija (pospanost), pretjerana dnevna pospanost (EDS), poremećaji cirkadijskog ritma, poremećaji spavanje/umor, umor, iscrpljenost povezana s apnejom u snu, poremećaj sna zbog perimenopauzalnih hormonalnih pomaka, umor povezan s Parkinsonovom bolesti, MS-povezan umor, umor povezan s depresijom, umor izazvan s kemoterapijom, poremećaji hranjenja, debljina, bolest putovanja, vertigo, šizofrenija, zlouporaba supstancija, bipolarni poremećaji, manični poremećaji i depresija kod sisavaca.
13. Najmanje jedan spoj izabran iz skupine koju čine: (4-ciklopropil-piperazin-1-il)-(4-morfolin-4-ilmetil-fenil)-metanon, (4-ciklopropil-piperazin-1-il)-[4-(4-fluoro-piperidin-1-ilmetil)-fenil]-metanon, (4-ciklopropil-piperazin-1-il)-(4-tiomorfolin-4-ilmetil-fenil)-metanon, te (4-ciklopropil-piperazin-1-il)-[4-(2-hidroksimetil-morfolin-4-ilmetil)-fenil]-metanon, te njihovi enantiomeri, hidrati, solvati i farmaceutski prihvatljive soli, naznačen time, da se koristi u liječenju ili prevenciji alergijskih reakcija gornjih dišnih puteva, astme, svrbeža, nazalne kongestije ili alergijskog rinitisa kod sisavaca.
14. Najmanje jedan spoj u skladu sa zahtjevom 1 te b) jedan ili više histaminskih H1 ili H2 antagonista, naznačeni time, da se koriste u liječenju ili prevenciji alergijskog rinitisa, nazalne kongestije i alergijske kongestije.
15. Najmanje jedan spoj u skladu sa zahtjevom 1 te b) jedan ili više blokatora ponovnog vezivanja neurotransmitera, naznačeni time, da se koriste u liječenju ili prevenciji depresije, poremećaja raspoloženja ili šizofrenije.
16. Najmanje jedan spoj u skladu sa zahtjevom 1 te b) modafinil, naznačeni time, da se koriste u liječenju ili prevenciji narkolepsije, pretjerane dnevne pospanosti (EDS), Alzheimer-ove bolesti, depresije, poremećaja deficita pozornosti, MS-povezanog umora, omamljenosti nakon anestezije, kognitivnog oštećenja, šizofrenije, spazma povezanog sa cerebralnom paralizom, slabljenja pamćenja zbog dobi, idiopatske somnolencije ili jet-lag.
17. Spoj u skladu sa zahtjevom 1, naznačen time, da je izotopno označen tako da se može prepoznati pomoću PET ili SPECT.
18. Spoj u skladu sa zahtjevom 1 koji je 18F-označen ili 11C-označen, naznačen time, da se koristi u postupku proučavanja poremećaja posredovanih histaminom, a navedeni postupak obuhvaća korak uporabe navedenog spoja kao molekularne probe pozitron emisijske tomografije (PET).
19. Farmaceutski pripravak u skladu sa zahtjevom 11, naznačen time, da nadalje sadrži topiramat.
20. Spoj izabran iz skupine koju čine: (4-ciklopropil-piperazin-1-il)-(4-morfolin-4-ilmetil-fenil)-metanon, (4-ciklopropil-piperazin-1-il)-[4-(4-fluoro-piperidin-1-ilmetil)-fenil]-metanon, (4-ciklopropil-piperazin-1-il)-(4-tiomorfolin-4-ilmetil-fenil)-metanon, te (4-ciklopropil-piperazin-1-il)-[4-(2-hidroksimetil-morfolin-4-ilmetil)-fenil]-metanon, te njihove farmaceutski prihvatljive soli, naznačen time, da se koristi u liječenju pojedinca koji pati od bolesti ili mu je dijagnosticirana bolest izabrana iz skupine koju čine: kognitivni poremećaji, poremećaji spavanja, psihijatrijski poremećaji i ostali poremećaji.
21. Spoj u skladu sa zahtjevom 20, naznačen time, da je bolest izabrana iz skupine koju čine: demencija, Alzheimer-ova bolest, kognitivna disfunkcija, blago kognitivno oštećenje, pre-demencija, hiperaktivni poremećaj s deficitom pozornosti, poremećaji deficita pozornosti te poremećaji učenja i pamćenja.
22. Spoj u skladu sa zahtjevom 21, naznačen time, da je bolest izabrana iz skupine koju čine: smanjena sposobnost učenja, smanjena sposobnost pamćenja i gubitak pamćenja.
23. Spoj u skladu sa zahtjevom 20, naznačen time, da je bolest izabrana iz skupine koju čine: insomnija, poremećeno spavanje, narkolepsija s ili bez pridružene katapleksije, katapleksija, poremećaj homeostaze spavanje/budnost, idiopatska somnolencija, pretjerana dnevna pospanost, poremećaji cirkadijskog ritma, umor, letargija i jet-lag.
24. Spoj u skladu sa zahtjevom 23, naznačen time, da je bolest izabrana iz skupine koju čine: apneja u snu, perimenopauzalni hormonalni pomaci, Parkinsonova bolest, multipla skleroza, depresija, kemoterapija te poremećaj zbog rada u smjenama.
25. Spoj u skladu sa zahtjevom 20, naznačen time, da je bolest izabrana iz skupine koju čine: šizofrenija, bipolarni poremećaji, manični poremećaji, depresija, opsesivno-konvulzivni poremećaj i post-traumatski stresni poremećaj.
26. Spoj u skladu sa zahtjevom 20, naznačen time, da je bolest izabrana iz skupine koju čine: bolest putovanja, vertigo, epilepsija, migrena, neurogena upala, poremećaji hranjenja, debljina i poremećaji zlouporabe supstancija.
27. Spoj u skladu sa zahtjevom 20, naznačen time, da je bolest izabrana iz skupine koju čine: depresija, poremećeno spavanje, umor, letargija, kognitivno oštećenje, smanjena sposobnost pamćenja, gubitak pamćenja, smanjena sposobnost učenja, poremećaji deficita pozornosti i poremećaji hranjenja.
28. Spoj u skladu sa zahtjevom 20, naznačen time, da je bolest izabrana iz skupine koju čine: slabljenje pamćenja zbog dobi, poremećaj REM-ponašanja, benigni posturalni vertigo, tinitus, poremećaji pokreta, sindrom nemirnih nogu, poremećaji povezani s očima, makularna degeneracija i retinitis pigmentosis.
HR20100263T 2005-09-16 2006-09-14 Ciklopropil amini kao modulatori histaminskog h3 receptora HRP20100263T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71765905P 2005-09-16 2005-09-16
PCT/US2006/035877 WO2007035425A2 (en) 2005-09-16 2006-09-14 Cyclopropyl amines as modulators of the histamine h3 receptor

Publications (1)

Publication Number Publication Date
HRP20100263T1 true HRP20100263T1 (hr) 2010-06-30

Family

ID=37889336

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20100263T HRP20100263T1 (hr) 2005-09-16 2006-09-14 Ciklopropil amini kao modulatori histaminskog h3 receptora

Country Status (32)

Country Link
US (3) US7687499B2 (hr)
EP (1) EP1948607B1 (hr)
JP (1) JP5185120B2 (hr)
KR (1) KR101336106B1 (hr)
CN (1) CN101321730B (hr)
AR (1) AR058670A1 (hr)
AT (1) ATE463481T1 (hr)
AU (1) AU2006292598B2 (hr)
BR (1) BRPI0622428A2 (hr)
CA (1) CA2622760C (hr)
CR (1) CR9891A (hr)
CY (1) CY1110167T1 (hr)
DE (1) DE602006013501D1 (hr)
DK (1) DK1948607T3 (hr)
EA (1) EA014370B1 (hr)
EC (1) ECSP088279A (hr)
ES (1) ES2342323T3 (hr)
HR (1) HRP20100263T1 (hr)
IL (1) IL190110A (hr)
ME (1) ME01181B (hr)
MX (1) MX2008003691A (hr)
MY (1) MY145305A (hr)
NO (1) NO340949B1 (hr)
NZ (1) NZ566533A (hr)
PL (1) PL1948607T3 (hr)
PT (1) PT1948607E (hr)
RS (1) RS51311B (hr)
SI (1) SI1948607T1 (hr)
TW (1) TWI418552B (hr)
UA (1) UA96424C2 (hr)
WO (1) WO2007035425A2 (hr)
ZA (1) ZA200803337B (hr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2561791A1 (en) * 2004-03-31 2005-10-20 Janssen Pharmaceutica, N.V. Non-imidazole heterocyclic compounds
PT1948607E (pt) 2005-09-16 2010-06-02 Janssen Pharmaceutica Nv Ciclopropilaminas como moduladores do receptor h3 de histamina
BRPI0618076A2 (pt) * 2005-10-31 2011-08-16 Janssen Pharmaceutica Nv processos para a preparação de derivados de ciclopropil-amida
US7795426B2 (en) * 2005-10-31 2010-09-14 Janssen Pharmaceutica Nv Processes for the preparation of cyclopropyl-amide derivatives
JP5285603B2 (ja) * 2006-05-30 2013-09-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒスタミンｈ３受容体のモジュレーターとしての置換ピリジルアミド化合物
US9108948B2 (en) * 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
NZ611323A (en) * 2006-06-23 2014-10-31 Abbvie Bahamas Ltd Cyclopropyl amine derivatives as histamin h3 receptor modulators
US20080045507A1 (en) * 2006-06-29 2008-02-21 Allison Brett D Substituted benzamide modulators of the histamine h3 receptor
TW200823204A (en) * 2006-10-17 2008-06-01 Arena Pharm Inc Biphenyl sulfonyl and phenyl-heteroaryl sulfonyl modulators of the histamine H3-receptor useful for the treatment of disorders related thereto
BRPI0721088B8 (pt) * 2006-12-14 2021-05-25 Janssen Pharmaceutica Nv processo para a preparação de derivados de piperazinil e diazepanil benzamida
SA08290520B1 (ar) 2007-08-22 2012-02-22 استرازينيكا ايه بي مشتقات سيكلو بروبيل أميد وتركيبات صيدلية تحتوي عليها لعلاج حالة مرضية سببها مستقبلات هيستامين h3
EP2222664B1 (en) 2007-11-20 2014-10-29 Janssen Pharmaceutica, N.V. Cycloalkyloxy- and heterocycloalkyloxypyridine compounds as modulators of the histamine h3 receptor
TW201039825A (en) 2009-02-20 2010-11-16 Astrazeneca Ab Cyclopropyl amide derivatives 983
US9186353B2 (en) * 2009-04-27 2015-11-17 Abbvie Inc. Treatment of osteoarthritis pain
WO2011102795A1 (en) 2010-02-18 2011-08-25 Astrazeneca Ab New crystalline form of a cyclopropyl benzamide derivative
BR112012020780A2 (pt) * 2010-02-18 2016-05-03 Astrazeneca Ab forma sólida, composição farmacêutica, e, uso de uma forma sólida.
LT3789038T (lt) 2010-05-14 2022-12-12 The Board Of Trustees Of The Leland Stanford Junior University Humanizuoti ir chimeriniai monokloniniai antikūnai prieš cd47
US8853390B2 (en) 2010-09-16 2014-10-07 Abbvie Inc. Processes for preparing 1,2-substituted cyclopropyl derivatives
US20130339859A1 (en) 2012-06-15 2013-12-19 Muzik LLC Interactive networked headphones
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US10088921B2 (en) 2014-10-10 2018-10-02 Muzik Inc. Devices for sharing user interactions
EP4251148A1 (en) 2020-11-27 2023-10-04 Richter Gedeon Nyrt. Histamine h3 receptor antagonists/inverse agonists for the treatment of autism spectrum disorder

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3714179A (en) 1970-09-08 1973-01-30 Searle & Co 1-alkyl-2-furfurylthioimidazoles and congeners
US3886160A (en) 1972-09-28 1975-05-27 Searle & Co 2-(2-Methyl-5-nitro-1-imidazolyl) ethyl-2-thiopseudoureas
FR2543139B1 (fr) * 1983-03-22 1985-08-16 Cerm Cent Europ Rech Mauvernay Derives de (1-alcoxy 2-amino) ethyl pyridine ou pyrazine, leur preparation et leur application en therapeutique
EP0186817B1 (en) 1984-12-10 1989-08-02 Nissan Chemical Industries Ltd. 3(2h)pyridazinone, process for its preparation and anti-allergic agent containing it
JP2813747B2 (ja) 1989-05-22 1998-10-22 富士写真フイルム株式会社 画像形成法
US5030644A (en) 1989-07-31 1991-07-09 Merck & Co., Inc. Imidazole compounds and their use as transglutaminase inhibitors
US5569659A (en) 1991-09-11 1996-10-29 Mcneilab, Inc. 4-arylpiperazines and 4-arylpiperidines
NZ240863A (en) 1991-09-11 1995-04-27 Mcneilab Inc Substituted 4-aryl piperidine and 4-aryl piperazine derivatives, preparation and pharmaceutical compositions thereof
US5217986A (en) 1992-03-26 1993-06-08 Harbor Branch Oceanographic Institution, Inc. Anti-allergy agent
US5352707A (en) 1992-03-26 1994-10-04 Harbor Branch Oceanographic Institution, Inc. Method for treating airway congestion
RU2124511C1 (ru) 1993-05-14 1999-01-10 Фармасьютикал Ко., Лтд Производные пиперазина
US5681954A (en) 1993-05-14 1997-10-28 Daiichi Pharmaceutical Co., Ltd. Piperazine derivatives
US5464788A (en) 1994-03-24 1995-11-07 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
EP0794779A4 (en) 1994-12-22 1998-04-29 Smithkline Beecham Corp FIBRINOGENIC RECEPTOR ANTAGONISTS
IL117149A0 (en) 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
US5889006A (en) 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
US6011029A (en) 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
JPH1059954A (ja) 1996-08-14 1998-03-03 Takeda Chem Ind Ltd 環状アミン誘導体およびそれを含んでなる医薬
US5869479A (en) 1997-08-14 1999-02-09 Schering Corporation Treatment of upper airway allergic responses
AU9650398A (en) 1997-11-07 1999-05-31 Daiichi Pharmaceutical Co., Ltd. Piperazine-cyclodextrin complexes
GB9803536D0 (en) 1998-02-19 1998-04-15 Black James Foundation Histamine H,receptor ligands
EP0978512A1 (en) 1998-07-29 2000-02-09 Societe Civile Bioprojet Non-imidazole aryloxy (or arylthio) alkylamines as histamine H3-receptor antagonists and their therapeutic applications
CN1468227A (zh) 2000-08-08 2004-01-14 ����-������ҩƷ��˾ 非咪唑芳氧基烷基胺
DE60126785T2 (de) 2000-08-08 2007-10-25 Ortho-Mcneil Pharmaceutical, Inc. Nicht-imidazol aryloxypiperidine als h3 rezeptor liganden
US7179912B2 (en) 2000-09-01 2007-02-20 Icos Corporation Materials and methods to potentiate cancer treatment
WO2002024695A2 (en) 2000-09-22 2002-03-28 Ortho Mcneil Pharmaceutical, Inc. Octahydro-indolizines and quinolizines and hexahydro-pyrrolizines
US6642226B2 (en) 2001-02-06 2003-11-04 Hoffman-La Roche Inc. Substituted phenyl-piperidine methanone compounds
EP1379493A2 (en) 2001-03-23 2004-01-14 Eli Lilly and Company Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses
WO2003000314A2 (en) 2001-06-20 2003-01-03 The Regents Of The University Of California Hemodialysis system and method
ATE449090T1 (de) 2001-07-02 2009-12-15 High Point Pharmaceuticals Llc Substituierte piperazin- und diazepanderivate zur verwendung als histamin h3 rezeptormodulatoren
JP4619655B2 (ja) 2001-09-14 2011-01-26 ハイ・ポイント・ファーマスーティカルズ、エルエルシー 新規アミノアゼチジン、−ピロリジンおよび−ピペリジン誘導体
EP1434765B1 (en) 2001-09-14 2009-12-02 High Point Pharmaceuticals, LLC Substituted piperidines with selective binding to histamine h3-receptor
WO2003031432A1 (en) 2001-10-12 2003-04-17 Novo Nordisk A/S Substituted piperidines and their use for the treatment of diseases related to the histamine h3 receptor
MXPA04005562A (es) 2001-12-10 2005-04-19 Johnson & Johnson Fenilalquinos.
WO2003055866A1 (en) 2001-12-21 2003-07-10 Bayer Pharmaceuticals Corporation Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
MXPA04007416A (es) 2002-02-01 2004-10-11 Novo Nordisk As Amidas de azetidinas, pirrolidinas, piperidinas y azepanos sustituidos como aminoalquilo.
IL162859A0 (en) * 2002-02-05 2005-11-20 Novo Nordisk As Novel aryl-and heteroarylpiperazines
MXPA05004384A (es) 2002-10-23 2005-10-18 Johnson & Johnson Piperacinil y diacepanil benzamidas y benztioamidas.
WO2005035534A1 (ja) 2003-10-08 2005-04-21 Ono Pharmaceutical Co., Ltd. 複素ビシクロ環および複素トリシクロ環化合物およびその医薬
GB0324159D0 (en) 2003-10-15 2003-11-19 Glaxo Group Ltd Novel compounds
BRPI0519288A2 (pt) 2004-12-24 2009-01-06 Astrazeneca Ab compostos heterocÍclicos como antagonistas de ccr2b
PT1948607E (pt) 2005-09-16 2010-06-02 Janssen Pharmaceutica Nv Ciclopropilaminas como moduladores do receptor h3 de histamina
US7514433B2 (en) 2006-08-03 2009-04-07 Hoffmann-La Roche Inc. 1H-indole-6-yl-piperazin-1-yl-methanone derivatives

Also Published As

Publication number Publication date
JP5185120B2 (ja) 2013-04-17
ECSP088279A (es) 2008-04-28
NO20081788L (no) 2008-05-29
WO2007035425A2 (en) 2007-03-29
HK1123291A1 (en) 2009-06-12
US7910582B2 (en) 2011-03-22
ME01181B (me) 2013-03-20
US20070066821A1 (en) 2007-03-22
CA2622760C (en) 2012-12-04
US7687499B2 (en) 2010-03-30
US8026242B2 (en) 2011-09-27
ZA200803337B (en) 2009-10-28
TWI418552B (zh) 2013-12-11
BRPI0622428A2 (pt) 2021-05-11
PT1948607E (pt) 2010-06-02
RS51311B (sr) 2010-12-31
EA014370B1 (ru) 2010-10-29
NO340949B1 (no) 2017-07-24
US20110136797A1 (en) 2011-06-09
EP1948607A2 (en) 2008-07-30
MY145305A (en) 2012-01-13
PL1948607T3 (pl) 2010-09-30
SI1948607T1 (sl) 2010-07-30
MX2008003691A (es) 2009-02-27
IL190110A (en) 2014-01-30
DK1948607T3 (da) 2010-07-26
KR20080056198A (ko) 2008-06-20
EP1948607B1 (en) 2010-04-07
JP2009508864A (ja) 2009-03-05
AU2006292598A1 (en) 2007-03-29
AU2006292598B2 (en) 2012-06-21
CY1110167T1 (el) 2015-01-14
US20100130485A1 (en) 2010-05-27
CN101321730A (zh) 2008-12-10
DE602006013501D1 (de) 2010-05-20
UA96424C2 (ru) 2011-11-10
WO2007035425A3 (en) 2008-07-24
IL190110A0 (en) 2008-12-29
TW200804337A (en) 2008-01-16
NZ566533A (en) 2010-11-26
AR058670A1 (es) 2008-02-20
CA2622760A1 (en) 2007-03-29
EA200800835A1 (ru) 2008-12-30
CN101321730B (zh) 2012-11-14
CR9891A (es) 2009-01-16
ATE463481T1 (de) 2010-04-15
KR101336106B1 (ko) 2013-12-05
ES2342323T3 (es) 2010-07-05

Similar Documents

Publication Publication Date Title
HRP20100263T1 (hr) Ciklopropil amini kao modulatori histaminskog h3 receptora
JP6240063B2 (ja) ヒストンデアセチラーゼ阻害剤
EA200800946A1 (ru) Антагонисты рецептора гистамина-3
RU2012129737A (ru) Замещенные бензамидные производные
JP2013537887A5 (hr)
NZ617334A (en) Cyclopropyl amine derivatives
JP2005539068A5 (hr)
MX2009007782A (es) Sal de tosilato de un compuesto terapeutico y composiciones farmaceuiticas de la misma.
Thomas et al. The pharmacology of Tourette syndrome
RU2007139541A (ru) Производные хромана и хромена и их применение
EA200901546A1 (ru) Дизамещенные амиды для усиления глутаматергических синаптических ответов
EA200970386A1 (ru) Бифенилсульфонильные и фенилгетероарилсульфонильные модуляторы гистаминового н3-рецептора, используемые для лечения ассоциированных с ним расстройств
JP2006510609A5 (hr)
HRP20201405T1 (hr) Derivat 5-etil-4-metil-pirazol-3-karboksamida, koji djeluje kao agonist taar-a
EA201000516A1 (ru) 3-замещенные 1,2,3-триазин-4-оны и 3-замещенные 1,3-пиримидин-оны для усиления глутаматергических синаптических ответов
JP2008501758A5 (hr)
NZ598083A (en) New compositions of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine
JP2009544579A5 (hr)
ME02375B (me) Heterociklički spojevi fenoksilmetila
RU2017104264A (ru) 2-окса-5-азабицикло[2.2.1]гептан-3-ильные производные
RU2016101085A (ru) Фенилкарбаматы и их применения в качестве ингибиторов фермента гидролазы амидов жирных кислот (faah) и модуляторов d3 допаминового рецептора (d3dr)
JP2011518858A5 (hr)
HRP20151003T1 (hr) Novi spojevi kao ligandi receptora histamina h3
HRP20110333T1 (hr) 4[(3-fluorfenoksi)fenilmetil]piperidin-metansulfonat: upotreba, postupci sinteze i farmaceutski pripravci
EA200801488A1 (ru) Замещенные фенетиламины, обладающие серотонинергической и/или норэпинефринергической активностью